GSK-HSD License Agreement GSK-HSD License Agreement [Member] GSK-HSD License Agreement Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Liability related to the sale of future royalties Beginning carrying value Ending carrying value Royalties, Liability, Noncurrent Royalties, Liability, Noncurrent Candidate costs Research And Development Expense, Candidate Costs Research And Development Expense, Candidate Costs Statistical Measurement [Domain] Statistical Measurement [Domain] Enrollment related milestone payments Enrollment Related Milestone Payments Enrollment Related Milestone Payments Debt Securities, Available-for-Sale Debt Securities, Available-for-Sale [Table Text Block] Realized gain on investments Realized Investment Gains (Losses) Bisirna Therapeutics, Inc Asset Transfer Agreement Bisirna Therapeutics, Inc Asset Transfer Agreement [Member] Bisirna Therapeutics, Inc Asset Transfer Agreement Award Timing Predetermined Award Timing Predetermined [Flag] 2026 (remainder) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Entity File Number Entity File Number Additional Paid-In Capital Additional Paid-in Capital [Member] Tabular List, Table Tabular List [Table Text Block] Leases [Abstract] Leases [Abstract] Annual installments period Cash Receivable Under Collaboration Agreement, Annual Installments Period Cash Receivable Under Collaboration Agreement, Annual Installments Period Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Construction In Progress Reclassified To Manufacturing Equipment Construction In Progress Reclassified To Manufacturing Equipment [Member] Construction In Progress Reclassified To Manufacturing Equipment Accounts payable Increase (Decrease) in Accounts Payable Contract assets included in other current assets Plus contract assets included in other current assets Contract assets Contract with Customer, Asset, after Allowance for Credit Loss, Current Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Accrued research and development expenses Accrued Research And Development Expense, Current Accrued Research And Development Expense, Current Basic (in dollars per share) Basic net income (loss) per share (in dollars per share) Earnings Per Share, Basic Adjustment to Compensation: Adjustment to Compensation [Axis] Related Party Disclosure Related Party Transactions Disclosure [Text Block] Schedule of Outstanding Balance of Credit Facility Schedule of Line of Credit Facilities [Table Text Block] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Regulatory milestone payments Regulatory Milestone Payments Regulatory Milestone Payments Schedule Of Stock By Class [Table] Stock, Class of Stock [Table] Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Options Share-Based Payment Arrangement, Option [Member] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Variable Interest Entity, Primary Beneficiary Variable Interest Entity, Primary Beneficiary [Member] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Stockholders’ equity Equity, Attributable to Parent Insider Trading Policies and Procedures [Line Items] Stock compensation Total Share-Based Payment Arrangement, Expense Schedule of Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Patents Patents [Member] Issuance of pre-funded warrants Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants Issuance of common stock under at-the-market offering, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues Current assets: Assets, Current [Abstract] Number of shares forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Total Liabilities, Noncontrolling Interest and Stockholders’ Equity Liabilities and Equity Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] License Licensing Agreements [Member] LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Cover [Abstract] Cover [Abstract] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Maximum Maximum [Member] Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price General and administrative expense General and Administrative Expense [Member] Useful Lives Finite-Lived Intangible Asset, Useful Life Net loss attributable to noncontrolling interest, net of tax Net Income (Loss) Attributable to Noncontrolling Interest Accounting Policies [Abstract] Accounting Policies [Abstract] Intangible assets, net Net Carrying Amount Finite-Lived Intangible Assets, Net Annual fees Additional Cash Receivable Under Collaboration Agreement Additional Cash Receivable Under Collaboration Agreement Schedule of Maturities of Operating Lease Liabilities on an Undiscounted Basis Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Common stock shares value reserved for future issuance Common Stock Capital Shares Value Reserved For Future Issuance Common stock, capital shares value reserved for future issuance. Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Development milestone payments Development Milestone Payments Development Milestone Payments Common Stock in Treasury Treasury Stock, Common [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Pay vs Performance Disclosure [Line Items] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] U.S. government and agency securities US Government Agencies Debt Securities [Member] Total operating lease liabilities (includes current portion) Operating Lease, Liability Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Supplemental disclosure of non-cash investing activities: Cash Flow, Noncash Investing Activities Disclosure [Abstract] Cash Flow, Noncash Investing Activities Disclosure Financing Agreement Financing Agreement [Member] Financing Agreement Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Income (loss) before income tax expense and noncontrolling interest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Entity Shell Company Entity Shell Company Facilities related Research And Development Expense, Facilities Related Expense Research And Development Expense, Facilities Related Expense 2013 Plan Two Thousands Thirteen Incentive Plan [Member] Two thousands thirteen incentive plan. Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Thereafter Long-Term Debt, Maturity, After Year Four Long-Term Debt, Maturity, After Year Four Sales-related milestone payments Sales Related Milestone Payments Sales-related milestone payments. Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Company Selected Measure Amount Company Selected Measure Amount 2029 Lessee, Operating Lease, Liability, to be Paid, Year Three Comprehensive loss attributed to noncontrolling interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Line of Credit Facility [Table] Line of Credit Facility [Table] Less: Unamortized debt issuance costs Debt Issuance Costs, Gross Cancelled or expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Name Measure Name Available-for-sale securities, Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Current Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Current Schedule of Stock-Based Compensation Expenses Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Accretion of note premiums/discounts Investment Income, Net, Amortization of Discount and Premium Secured Debt Secured Debt [Member] Lease liabilities Operating Lease, Liability, Current Collaboration and License Agreements Collaboration And License Agreements [Member] Collaboration And License Agreements Class Of Stock [Line Items] Class of Stock [Line Items] Document Fiscal Period Focus Document Fiscal Period Focus Number of distinct performance obligations Number Of Distinct Performance Obligations Number of distinct performance obligations. Percentage of commission to sales agent Percentage Of Commission On Aggregate Gross Proceeds From Sale Of Common Stock Percentage of commission on aggregate gross proceeds from sale of common stock. Award Timing Method Award Timing Method [Text Block] Furniture Furniture and Fixtures [Member] Award Type Award Type [Axis] Deferred revenue, net of current portion Contract liabilities included in deferred revenue, non-current Deferred revenue, non-current Contract with Customer, Liability, Noncurrent Commercial notes Commercial Notes [Member] Commercial Notes Total Assets Assets Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] 2027 Finite-Lived Intangible Asset, Expected Amortization, Year One Trading Symbol Trading Symbol 2030 Lessee, Operating Lease, Liability, to be Paid, Year Four Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Capped call, price per share (in dollars per share) Debt Instrument, Capped Call, Price Per Share Debt Instrument, Capped Call, Price Per Share Warrant option term Sale Of Stock, Option Term Sale Of Stock, Option Term Geographical [Domain] Geographical [Domain] Entity Address, City or Town Entity Address, City or Town Short-Term Debt, Type [Domain] Short-Term Debt, Type [Domain] Pre-Funded Warrants Pre-Funded Warrants [Member] Pre-Funded Warrants 2031 and thereafter Lessee Operating Lease, Liability, To Be Paid, Year Five And After Year Five Lessee operating lease liability payments due year five and after year five. CASH FLOWS FROM OPERATING ACTIVITIES: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Organization and Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Research Facility in San Diego Research Facility In San Diego [Member] Research Facility in San Diego. Development regulatory and sales milestones payments Development Regulatory And Sales Milestones Payments Development regulatory and sales milestones payments. Intangible Assets Intangible Assets Disclosure [Text Block] Effect of exchange rate on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Accrued research and development expenses; co-development Accrued Research And Development Co-Development Expense, Current Accrued Research And Development Co-Development Expense, Current Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount 2013 and 2021 Incentive Plans and other inducement grants Two Thousand Thirteen Equity Incentive Plan, Two Thousand Twenty One Equity Incentive Plan And Inducement Grants [Member] Two Thousand Thirteen Equity Incentive Plan, Two Thousand Twenty One Equity Incentive Plan And Inducement Grants Restricted stock units Restricted Stock Units (RSUs) [Member] Income Statement Location [Domain] Statement of Income Location, Balance [Domain] CASH, CASH EQUIVALENTS AND RESTRICTED CASH: Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation [Abstract] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] 2030 Finite-Lived Intangible Asset, Expected Amortization, Year Four Entity Emerging Growth Company Entity Emerging Growth Company 2029 Long-Term Debt, Maturity, Year Three Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Right-of-use assets adjusted in exchange for new/amended operating lease liabilities Right-Of-Use Asset Adjustment In Exchange For Operating Lease Liability Right-Of-Use Asset Adjustment In Exchange For Operating Lease Liability Lease Cost Lease, Cost [Abstract] Convertible Senior Notes Convertible Senior Notes Due 2032 [Member] Convertible Senior Notes Due 2032 Number of options outstanding (in shares) Options (in shares) Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Common stock, shares outstanding (in shares) Common stock, beginning balance (in shares) Common stock, ending balance (in shares) Common Stock, Shares, Outstanding Plan Name Plan Name [Axis] PEO PEO [Member] Number of new target programs Number Of New Target Programs Number Of New Target Programs Non-cash interest expense on liability related to the sale of future royalties Non-cash interest expense recognized Noncash Interest Expense, Liability Related to Sale of Future Royalties Noncash Interest Expense, Liability Related to Sale of Future Royalties Schedule of Revenue Disaggregation of Revenue [Table Text Block] Schedule of Contract Maturity of Available for Sale Securities Investments Classified by Contractual Maturity Date [Table Text Block] Proceeds from sales and maturities of investments Proceeds from Sale, Maturity and Collection of Investments Gain on settlement of treasury stock Gain (Loss) On Treasury Stock Settlement Gain (Loss) On Treasury Stock Settlement Accrued income taxes Accrued Income Taxes, Current Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Schedule of Intangible Assets Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Proceeds from equity offering Proceeds from Issuance or Sale of Equity Accumulated Deficit Retained Earnings [Member] Number of RSUs Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restatement Determination Date Restatement Determination Date Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Income Statement [Abstract] Income Statement [Abstract] Cash, cash equivalents and restricted cash BEGINNING OF PERIOD END OF PERIOD Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income tax expense Income Tax Expense (Benefit) Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Sale of Stock [Domain] Sale of Stock [Domain] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Schedule of Company's Current Pipeline Schedule of Current Products [Table Text Block] Schedule of Current Products Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Available-for-sale securities, Adjusted Basis Debt Securities, Available-for-Sale, Amortized Cost, Current Contractual interest expense Interest Expense, Debt, Excluding Amortization Property, plant and equipment, gross Property, Plant and Equipment, Gross Sanofi Sanofi [Member] Sanofi Net income (loss) including noncontrolling interest Net income (loss) Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Inducement Awards Inducement Awards [Member] Inducement Awards Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Cash paid for amounts included in the measurement of lease liabilities: Cash Flow, Operating Activities, Lessee [Abstract] Research equipment Research Equipment [Member] Research Equipment Initial transaction price Initial Transaction Price Initial transaction price. Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Public Offering Public Offering [Member] Public Offering Proceeds from the exercises of stock options Proceeds from Stock Options Exercised Total transaction price Collaboration Arrangement, Consideration Collaboration Arrangement, Consideration City Area Code City Area Code Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Inducement Plan Inducement Plan [Member] Inducement Plan All Trading Arrangements All Trading Arrangements [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Schedule of Liability Related to the Sale of Future Royalties Schedule Of Liability Related To The Sale Of Future Royalties [Table Text Block] Schedule Of Liability Related To The Sale Of Future Royalties Accrued expenses Total accrued expenses Accrued Liabilities, Current Share-based payment award (in shares) Restricted stock units (in shares) Beginning of period (in shares) End of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Schedule of Receivables and Contract Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Commercial milestone payments at first commercial sale Commercial Milestone Payments At First Commercial Sale Commercial milestone payments at first commercial sale. CASH FLOWS FROM INVESTING ACTIVITIES: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] General and administrative Total general and administrative expense General and Administrative Expense Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Net cash provided by (used in) operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Short-term investments, Amortized Cost Other Short-Term Investments, Amortized Cost Other Short-Term Investments, Amortized Cost Debt instrument term Debt Instrument, Term Related Party Transactions [Abstract] Future potential milestone payments Future Potential Milestone Payments Future Potential Milestone Payments Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Useful life Property, Plant and Equipment, Useful Life Subsequent Event Subsequent Event [Member] Total Lease, Cost Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Schedule of Lease Assets and Liabilities and Lease Cost Lease, Cost [Table Text Block] PEO Total Compensation Amount PEO Total Compensation Amount Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Money market instruments Money Market Funds [Member] 2026 (remainder) Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Numerator: Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Additional remaining development regulatory and sales milestones payments Additional Remaining Development Regulatory And Sales Milestones Payments Additional remaining development regulatory and sales milestones payments. 2021 Plan Two Thousand Twenty One Incentive Plan [Member] Two thousand twenty one incentive plan. Common Stock Equity Components [Axis] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Financing Agreement, Initial Term Loan Financing Agreement, Initial Term Loan [Member] Financing Agreement, Initial Term Loan Common stock - restricted stock units vesting Stock Issued During Period, Value, Restricted Stock Award, Gross Wisconsin WISCONSIN Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Sanofi License Agreement Sanofi License Agreement [Member] Sanofi License Agreement Number of reportable segments Number of Reportable Segments Covenant, convertible indebtedness outstanding maximum Debt Instrument, Covenant, Convertible Indebtedness Outstanding, Maximum Debt Instrument, Covenant, Convertible Indebtedness Outstanding, Maximum Cancelled or expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Supplemental disclosure of cash flows: Supplemental Cash Flow Information [Abstract] Other Performance Measure, Amount Other Performance Measure, Amount Weighted- Average Exercise Price Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Payments of debt issuance costs Payments of Debt Issuance Costs Entity Address, State or Province Entity Address, State or Province Total research and development expense, excluding non-cash expense Research And Development Expense, Excluding Noncash Expense Research And Development Expense, Excluding Noncash Expense Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Total current liabilities Liabilities, Current Over-Allotment Option Over-Allotment Option [Member] Operating Segment Operating Segment [Member] Operating Segment Covenant, aggregate convertible indebtedness outstanding, maximum Debt Instrument, Covenant, Aggregate Convertible Indebtedness Outstanding, Maximum Debt Instrument, Covenant, Aggregate Convertible Indebtedness Outstanding, Maximum Net decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation Milestone payment Milestone Payment Earned Milestone payment earned. Common stock - restricted stock units vesting (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Individual: Individual [Axis] Net income (loss) per share attributable to Arrowhead Pharmaceuticals, Inc.: Earnings Per Share Reconciliation [Abstract] Other current assets Other Assets, Current Research and development Research and Development Expense [Member] Number of performance obligations Number Of Performance Obligations Number Of Performance Obligations Additional paid-in capital Additional Paid in Capital, Common Stock Net cash (used in) provided by investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] MOIC payments expected to be applied to principal upon repayment Debt Instrument, Multiple Of Investment Capital Expected To Be Applied To Principal Upon Repayment Debt Instrument, Multiple Of Investment Capital Expected To Be Applied To Principal Upon Repayment Capital expenditures incurred Commitments, Capital Expenditures Incurred To Date Commitments, Capital Expenditures Incurred To Date Manufacturing equipment Manufacturing equipment Manufacturing Equipment [Member] Manufacturing Equipment Document Fiscal Year Focus Document Fiscal Year Focus Right-of-use assets Operating Lease, Right-of-Use Asset Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Entity Interactive Data Current Entity Interactive Data Current Operating lease cost Operating Lease, Cost Plan Name Plan Name [Domain] Weighted average period to recognize pre-tax compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Olpasiran Agreement Olpasiran Agreement [Member] Olpasiran agreement. Exercise of stock options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Equity [Abstract] Equity [Abstract] Proceeds from additional tenant improvement allowance Proceeds From Tenant Improvement Allowance Proceeds From Tenant Improvement Allowance Aggregate Intrinsic Value, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Buildings Building [Member] Segment Information Segment Reporting Disclosure [Text Block] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Planned area of site (in sq ft) Area of Land Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Other Commitments [Line Items] Other Commitments [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Equity premium Sale Of Stock, Premium On Issuance Of Shares Sale Of Stock, Premium On Issuance Of Shares Finite Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Milestone payment receivable upon achievement of phase two and first patient dosed in phase three Milestone Payment Receivable Upon Achievement Of Phase Two And First Patient Dosed In Phase Three Milestone payment receivable upon achievement of phase two and first patient dosed in phase three. Computers and software Computers And Software [Member] Computers And Software Drug Manufacturing Facility Drug Manufacturing Facility [Member] Drug manufacturing facility. Number of warrants exercised (in shares) Class Of Warrant Or Right, Number Of Warrants Exercised Class Of Warrant Or Right, Number Of Warrants Exercised Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Amortization expense Amortization of Intangible Assets Restricted cash Restricted Cash and Cash Equivalent, Current Collaboration And License Agreements [Abstract] Collaboration And License Agreements [Abstract] Collaboration and license agreements. Depreciation and amortization expense for property and equipment Depreciation/amortization Depreciation, Depletion and Amortization Other assets Other Assets, Noncurrent Entity Central Index Key Entity Central Index Key PEO Name PEO Name Schedule of Principal Repayment Related to Credit Facility Schedule of Maturities of Long-Term Debt [Table Text Block] Proceeds from sale of stock Sale of Stock, Consideration Received on Transaction Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Financing Agreement, MOIC Payment Financing Agreement, MOIC Payment [Member] Financing Agreement, MOIC Payment Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Revolving Credit Facility Revolving Credit Facility [Member] Other comprehensive income (loss), net of tax: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Arrangement Duration Trading Arrangement Duration Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Development and sales milestone payments Development And Sales Milestones Payments Development And Sales Milestones Payments Deferred revenue Contract liabilities included in deferred revenue, current Less deferred revenue, current Contract with Customer, Liability, Current Segments [Axis] Segments [Axis] Warrant exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Exercise Price Award Exercise Price Liability, Sale Of Future Royalties [Roll Forward] Liability, Sale Of Future Royalties [Roll Forward] Liability, Sale Of Future Royalties Entity Filer Category Entity Filer Category Class of Stock [Domain] Class of Stock [Domain] Local Phone Number Local Phone Number Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Unrecognized pre-tax compensation expense Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Stock-Based Compensation Share-Based Payment Arrangement [Text Block] ASSETS Assets [Abstract] Credit facility, net of current portion Long-Term Debt, Excluding Current Maturities Credit Facility [Axis] Credit Facility [Axis] Construction In Progress Reclassified To Building Construction In Progress Reclassified To Building [Member] Construction In Progress Reclassified To Building Number of options to renew Number Of Options To Renew Number of options to renew. Takeda Pharmaceutical Company Limited Takeda Pharmaceuticals United States Of America Incorporated [Member] Takeda Pharmaceuticals United States of America Incorporated. Underlying Security Market Price Change Underlying Security Market Price Change, Percent Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Three Debt Instrument [Axis] Debt Instrument [Axis] Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Fair Value Measurements Fair Value Disclosures [Text Block] Term deposit Bank Time Deposits [Member] Credit Facility [Domain] Credit Facility [Domain] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Collaboration arrangement, written notice period Collaboration Arrangement, Termination Notice Period After Regulatory Approval Collaboration Arrangement, Termination Notice Period After Regulatory Approval Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Value of stock repurchased Treasury Stock, Value, Acquired, Cost Method Research and development Total research and development expense Research and Development Expense Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] Interest rate Debt Instrument, Interest Rate, Stated Percentage Lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Liability Related to the Sale of Future Royalties Liability Related To The Sale Of Future Royalties [Text Block] Liability Related To The Sale Of Future Royalties Schedule of Shares of Common Stock and Preferred Stock Schedule of Stock by Class [Table Text Block] James Hamilton [Member] James Hamilton Fair Value as of Grant Date Award Grant Date Fair Value Receivables included in accounts receivable Accounts Receivable, after Allowance for Credit Loss Entity Registrant Name Entity Registrant Name Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Municipal securities Municipal Bonds [Member] Milestone payment received Milestone Payment Received, Liability Related To Sale Of Future Royalties Milestone Payment Received, Liability Related To Sale Of Future Royalties Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Cash received for amounts included in the measurement of lease liabilities: Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities [Abstract] Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities Deferred revenue additions Contract with Customer, Liability, Increase from Deferral Of Revenue Contract with Customer, Liability, Increase from Deferral Of Revenue Purchases of investments Payments to Acquire Investments Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Document Quarterly Report Document Quarterly Report Total financial assets Assets, Fair Value Disclosure Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Counterparty Name [Domain] Counterparty Name [Domain] R&D discovery costs Research And Development Expense, Discovery Costs Research And Development Expense, Discovery Costs Number of operating segments Number of Operating Segments 2028 Lessee, Operating Lease, Liability, to be Paid, Year Two Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Weighted- Average Remaining Contractual Term (Years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Title Trading Arrangement, Individual Title Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Number of shares exchanged for each equity instrument Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Number Of Shares Exchanged For Each Equity Instrument Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Number Of Shares Exchanged For Each Equity Instrument Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Repayments of credit facility Repayments of credit facility Less: Payments Repayments of Long-Term Lines of Credit Restatement Determination Date: Restatement Determination Date [Axis] Liability Related To The Sale Of Future Royalties [Abstract] Liability Related To The Sale Of Future Royalties Non-PEO NEO Non-PEO NEO [Member] Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Total interest expense Interest Expense, Debt Sale of Stock [Axis] Sale of Stock [Axis] Land Land [Member] Annual installment Cash Receivable Under Collaboration Agreement, Annual Installments Cash Receivable Under Collaboration Agreement, Annual Installments Name Trading Arrangement, Individual Name Award Type Award Type [Domain] Facilities related General And Administrative Expense, Facilities Related Expense General And Administrative Expense, Facilities Related Expense 2027 Lessee, Operating Lease, Liability, to be Paid, Year One Noncontrolling interest Equity, Attributable to Noncontrolling Interest Equity Awards Adjustments Equity Awards Adjustments [Member] Leasehold improvements Leasehold Improvements [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Number of plans Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Plans Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Plans Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Debt instrument, face amount Debt Instrument, Face Amount Increase (decrease) in cash and investments Increase (Decrease) In Cash And Investments Increase decrease in cash and investments. License and Co-Funding Agreement License And Co Funding Agreement [Member] License and co-funding agreement. Schedule of Awards Outstanding Share-Based Payment Arrangement, Activity [Table Text Block] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Certificate of deposits Certificates of Deposit [Member] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Revenue recognized Contract with Customer, Liability, Revenue Recognized MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Name Awards Close in Time to MNPI Disclosures, Individual Name Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value ATM Agreement At-The-Market Agreement [Member] At-The-Market Agreement Corporate Headquarters In Pasadena Corporate Headquarters In Pasadena [Member] Corporate Headquarters in Pasadena Weighted-average shares used in calculating Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Number of distinct bundle Number Of Distinct Bundle Number of distinct bundle. Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Royalty payment threshold Royalty Payment Threshold Royalty Payment Threshold 2027 Long-Term Debt, Maturity, Year One Financial Instruments [Domain] Financial Instruments [Domain] Unrealized gains (losses) on available-for-sale securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Facilities Facilities [Member] Facilities. Segments [Domain] Segments [Domain] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Line of credit facility, remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Consolidated Entity Excluding Variable Interest Entities (VIE) Consolidated Entity, Excluding Consolidated VIE [Member] Inventory Increase (Decrease) in Inventories Credit facility Less: Current portion of credit facility Line of Credit, Current Finite-Lived Intangible Assets by Major Class Finite-Lived Intangible Assets by Major Class [Axis] Number of securities called by warrants (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Minimum Minimum [Member] Less: Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Company Selected Measure Name Company Selected Measure Name Property, plant and equipment, reclassification Property, Plant and Equipment, Transfers and Changes Senior Notes Senior Notes [Member] Royalty Pharma Agreement Royalty Pharma Agreement [Member] Royalty Pharma Agreement Sarepta Sarepta Therapeutics, Inc [Member] Sarepta Therapeutics, Inc Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Accounts payable Accounts Payable, Current Accumulated interest on the Initial Term Loan Interest Payable Operating cash flows from operating leases Operating Lease, Payments Upfront payment Proceeds from collaboration arrangements Proceeds From Collaboration Arrangements Proceeds From Collaboration Arrangements Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] All Executive Categories All Executive Categories [Member] Schedule of Total Interest Expense Recognized Summary Of Interest Expense Recognized Related To Credit Facility [Table Text Block] Summary Of Interest Expense Recognized Related To Credit Facility Upfront payment received Upfront Payment Received, Liability Related To Sale Of Future Royalties Upfront Payment Received, Liability Related To Sale Of Future Royalties Common stock, $0.001 par value: Authorized 290,000 shares; 140,052 shares issued and 137,391 outstanding as of December 31, 2025 and 138,363 shares issued and 135,702 outstanding as of September 30, 2025 Common Stock, Value, Issued Operating cash flows from operating leases Operating Lease, Cash Received For Amounts Included In Measurement Of Lease Liabilities Operating Lease, Cash Received For Amounts Included In Measurement Of Lease Liabilities Available-for-sale securities, at fair value and short-term investments Total current Investments, Fair Value Short-Term Investments Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Milestone payment due from collaborative agreement Milestone Payment Due From Collaborative Agreement Milestone Payment Due From Collaborative Agreement Diluted (in shares) Weighted-average diluted shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Total current Investments, Amortized Cost Short-Term Investments, Amortized Cost Short-Term Investments, Amortized Cost Commitments and contingencies (Note 7) Commitments and Contingencies Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Other comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Entity Small Business Entity Small Business Amgen Incorporated Amgen Incorporated [Member] Amgen Incorporated. Non- controlling Interest Noncontrolling Interest [Member] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Asset acquisition, equity interest Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable Financing Agreement Long-Term Debt [Text Block] Document Transition Report Document Transition Report Underlying Securities Award Underlying Securities Amount Covenant, market capitalization threshold Debt Instrument, Covenant, Market Capitalization, Threshold Debt Instrument, Covenant, Market Capitalization, Threshold Equity Component Equity Component [Domain] Document Period End Date Document Period End Date After one to two years Short-Term Investments, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One Through Two Short-Term Investments, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One Through Two PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Credit facility, net of current portion Long-Term Line of Credit, Noncurrent Balance Sheet Accounts Supplemental Balance Sheet Disclosures [Text Block] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Short-term lease cost Short-Term Lease, Cost Weighted-Average Remaining Contractual Term, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Operating lease, net Increase (Decrease) in Operating Lease Liability Total noncontrolling interest and stockholders’ equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Common stock repurchase price per share (in dollars per share) Shares Acquired, Average Cost Per Share Accretion of the MOIC Payment Amortization of Debt Discount (Premium) Document Type Document Type Level 3 Fair Value, Inputs, Level 3 [Member] Net Income (Loss) Per Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name California CALIFORNIA Asset Acquisition Asset Acquisition [Domain] Number of collaboration programs Number Of Collaboration Programs Number Of Collaboration Programs Proceeds from the issuance of common stock, net of issuance costs paid Proceeds from Issuance of Common Stock Variable lease cost Variable Lease, Cost Revenue Revenue from Contract with Customer, Excluding Assessed Tax All Individuals All Individuals [Member] Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Name Forgone Recovery, Individual Name Total current assets Assets, Current Milestone payment receivable upon FDA approval Milestone Payment Receivable, Upon FDA Approval Milestone Payment Receivable, Upon FDA Approval Lease Assets and Liabilities Assets and Liabilities, Lessee [Abstract] Statistical Measurement [Axis] Statistical Measurement [Axis] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Contingent liabilities Loss Contingency Accrual Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial Milestone Payment Receivable, Upon Achievement of Enrollment in Phase 3 Clinical Trial Milestone Payment Receivable, Upon Achievement of Enrollment in Phase 3 Clinical Trial Triggered milestone payments Triggered Milestone Payments Triggered Milestone Payments Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Private Placement Private Placement [Member] Impairment Finite-Lived Intangible Assets, Impairment Finite-Lived Intangible Assets, Impairment Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Short-term investments, Fair Value Short‑term investments Short Term Investments, Fair Value Disclosure Short Term Investments, Fair Value Disclosure Office space leases (in sq ft) Land Subject to Ground Leases Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Schedule Of Finite Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] Current liabilities: Liabilities, Current [Abstract] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Geographical [Axis] Geographical [Axis] Variable consideration Collaboration Arrangement, Variable Consideration Collaboration Arrangement, Variable Consideration Lessee Lease Description [Line Items] Lessee, Lease, Description [Line Items] Other Increase (Decrease) in Other Operating Assets and Liabilities, Net Total operating expenses Operating Expenses Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Long-term line of credit Long-Term Line of Credit Level 1 Fair Value, Inputs, Level 1 [Member] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Accrued expenses Increase (Decrease) in Accrued Liabilities Diluted (in dollars per share) Diluted net income (loss) per share (in dollars per share) Earnings Per Share, Diluted Percentage of eligible to receive tiered royalties on net sales Percentage Of Eligible To Receive Tiered Royalties On Net Sales Percentage of eligible to receive tiered royalties on net sales. Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Title of 12(b) Security Title of 12(b) Security Lessee Lease Description [Table] Lessee, Lease, Description [Table] Multiple of invested capital rate Debt Instrument, Covenant, Multiple Of Invest Capital Debt Instrument, Covenant, Multiple Of Invest Capital Shares of common stock issued (in shares) Sale of Stock, Number of Shares Issued in Transaction Treasury stock (in shares) Treasury stock, beginning balance (in shares) Treasury stock, ending balance (in shares) Treasury Stock, Common, Shares Non-cash interest expense on credit facility Paid-in-Kind Interest Earnings Per Share [Abstract] Total other expense Nonoperating Income (Expense) Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Awards granted and outstanding (in shares) Total (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding Salaries Research And Development Expense, Salaries Expense Research And Development Expense, Salaries Expense Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Covenant, minimum liquidity cash, cash equivalents and investments Debt Instrument, Covenant, Minimum Liquidity If Capitalization Is Above Threshold Debt Instrument, Covenant, Minimum Liquidity If Capitalization Is Above Threshold Available-for-sale securities, Fair Value Debt Securities, Available-for-Sale, Current Deferred revenue Increase (Decrease) in Contract with Customer, Liability Debt instrument, prepayment percentage Debt Instrument, Prepayment, Percentage Debt Instrument, Prepayment, Percentage Short-Term Debt, Type [Axis] Short-Term Debt, Type [Axis] Within one year Short-Term Investments, Fair Value, Maturity, Allocated And Single Maturity Date, Remainder Of Fiscal Year Short-Term Investments, Fair Value, Maturity, Allocated And Single Maturity Date, Remainder Of Fiscal Year Fixed consideration Collaboration Arrangement, Fixed Consideration Collaboration Arrangement, Fixed Consideration Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Common stock repurchased (in shares) Treasury Stock, Shares, Acquired Income taxes paid Income Taxes Paid, Net Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Two Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] GSK Glaxosmithkline Intellectual Property Limited [Member] Glaxosmithkline Intellectual Property Limited. Award Timing Disclosures [Line Items] Initial Term Loan Total Long-Term Debt, Gross Colorado Owner, LLC Colorado Owner L L C [Member] Colorado Owner, LLC. Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Available-for-sale securities, Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Current Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Current Capped call, premium percentage Debt Instrument, Capped Call, Premium Percentage Debt Instrument, Capped Call, Premium Percentage Accrued payroll and benefits Employee-related Liabilities, Current Total Lessee, Operating Lease, Liability, to be Paid Operating lease renewal term Lessee, Operating Lease, Renewal Term Number of agreements Number Of Agreements Number of agreements. Lease extension period Lessee, Operating Lease, Extension Period Lessee, Operating Lease, Extension Period Stockholders' Equity Equity [Text Block] Sarepta Collaboration Agreement Sarepta Collaboration Agreement [Member] Sarepta Collaboration Agreement Dividends declared by variable interest entity to noncontrolling shareholders Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Net income (loss) attributable to Arrowhead Pharmaceuticals, Inc. Net income (loss) attributable to Arrowhead Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent Subsequent Event [Table] Subsequent Event [Table] Expiration Date Trading Arrangement Expiration Date Long-term liabilities: Liabilities, Noncurrent [Abstract] Construction in progress Construction in Progress [Member] Other Other Accrued Liabilities, Current Novartis Novartis Pharma AG [Member] Novartis Pharma AG Noncontrolling interest and stockholders’ equity: Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Adoption Date Trading Arrangement Adoption Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Accounts receivable Increase (Decrease) in Accounts Receivable Series A Preferred Stock Series A Preferred Stock [Member] Entity Current Reporting Status Entity Current Reporting Status Lease term Lessee, Operating Lease, Term of Contract Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Operating income (loss) Operating Income (Loss) Line of Credit Line of Credit [Member] Consolidated Entities [Domain] Consolidated Entities [Domain] Accumulated deficit Retained Earnings (Accumulated Deficit) Financial Instrument [Axis] Financial Instrument [Axis] Visirna ESOP Visirna ESOP [Member] Visirna ESOP Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Executive Category: Executive Category [Axis] Milestone payment receivable upon receipt of royalty payments Milestone Payment Receivable, Upon Receipt Of Royalty Payments Milestone Payment Receivable, Upon Receipt Of Royalty Payments Class of Stock [Axis] Class of Stock [Axis] Current Fiscal Year End Date Current Fiscal Year End Date Subsequent Event Type [Domain] Subsequent Event Type [Domain] Finite-Lived Intangible Assets, Major Class Name Finite-Lived Intangible Assets, Major Class Name [Domain] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Christopher Anzalone [Member] Christopher Anzalone Liability related to the sale of future royalties, interest rate Liability, Sale Of Future Royalties, Interest Rate Liability, Sale Of Future Royalties, Interest Rate Professional, outside services, and other Professional Fees Weighted- Average Grant Date Fair Value Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Common stock, share reserve for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Other, net Other Nonoperating Income (Expense) Statement [Table] Statement [Table] Adjustments to reconcile net income (loss) to net cash flow from operating activities Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Covenant, convertible indebtedness outstanding, marked capitalization percentage, maximum Debt Instrument, Covenant, Convertible Indebtedness Outstanding, Market Capitalization Percentage, Maximum Debt Instrument, Covenant, Convertible Indebtedness Outstanding, Market Capitalization Percentage, Maximum Collaboration and License Agreements Collaborative Arrangement Disclosure [Text Block] CASH FLOWS FROM FINANCING ACTIVITIES: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Schedule of Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Potentially dilutive securities excluded from computation of diluted earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount All Adjustments to Compensation All Adjustments to Compensation [Member] Capped call, transaction costs Debt Instrument, Capped Call, Transaction Costs Debt Instrument, Capped Call, Transaction Costs Amendment Flag Amendment Flag Salaries Salary and Wage, Excluding Cost of Good and Service Sold Common stock sold price (in dollars per share) Sale of Stock, Price Per Share 2028 Long-Term Debt, Maturity, Year Two Number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Treasury stock; at cost; 2,661 shares of common stock at December 31, 2025 and September 30, 2025 Treasury stock value Treasury Stock, Common, Value Other Commitments [Table] Other Commitments [Table] Leases Lessee, Operating Leases [Text Block] Termination Date Trading Arrangement Termination Date Net cash (used in) provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Collaboration agreement termination notice period prior to any regulatory approval of a licensed product Collaboration Arrangement, Termination Notice Period Prior To Regulatory Approval Collaboration Arrangement, Termination Notice Period Prior To Regulatory Approval Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Paid-In-Full Warrants Paid-In-Full Warrants [Member] Paid-In-Full Warrants Measure: Measure [Axis] Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Basic (in shares) Weighted-average basic shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Movement In Contract With Customer Liability [Roll Forward] Movement In Contract With Customer Liability [Roll Forward] Movement In Contract With Customer Liability Issuance of pre-funded warrants (in shares) Stock And Warrants Issued During Period, Shares, Preferred Stock And Warrants Stock And Warrants Issued During Period, Shares, Preferred Stock And Warrants Schedule of Computation of Basic and Diluted Net (Loss) Income Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Warrants purchase price (in dollars per share) Class of Warrant or Right, Purchase Price of Warrants or Rights Class of Warrant or Right, Purchase Price of Warrants or Rights Accrued capital expenditures Accrued Capital Expenditure, Current Accrued Capital Expenditure, Current Milestone payment receivable Milestone Payment Receivable Milestone Payment Receivable Number of Options Outstanding, Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Subsequent Events [Abstract] Subsequent Events [Abstract] Segment Reporting [Abstract] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Debt Disclosure [Abstract] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Amortization of debt issuance costs Amortization of Debt Issuance Costs Other (expense) income: Nonoperating Income (Expense) [Abstract] Entity Tax Identification Number Entity Tax Identification Number Asset Acquisition Asset Acquisition [Axis] Proceeds from debt and equity issuance Proceeds From Issuance Of Long-Term Debt And Issuance Of Equity Proceeds From Issuance Of Long-Term Debt And Issuance Of Equity Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Four Finite-Lived Intangible Asset, Expected Amortization, after Year Four Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Consolidated Entities [Axis] Consolidated Entities [Axis] Common stock, shares issued (in shares) Common Stock, Shares, Issued 2030 Long-Term Debt, Maturity, Year Four Weighted-average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Granted (in shares) Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Dividends declared by variable interest entity to noncontrolling shareholders Dividends Payable, Current Interest expense Interest Expense, Nonoperating Trading Arrangement: Trading Arrangement [Axis] Total Shareholder Return Amount Total Shareholder Return Amount GSK-HBV Agreement GSK-HBV Agreement [Member] GSK-HBV Agreement Subsequent Events Subsequent Events [Text Block] Foreign currency translation adjustments Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Insider Trading Arrangements [Line Items] Proceeds from the issuance of pre-funded warrants Proceeds from Issuance of Warrants Security Exchange Name Security Exchange Name Accumulated accretion of the MOIC Payment Debt Instrument, Accumulated Accretion Debt Instrument, Accumulated Accretion Interest income Investment Income, Interest and Dividend Total general and administrative expense, excluding non-cash expense General And Administrative Expense, Excluding Noncash Expense General And Administrative Expense, Excluding Noncash Expense Asset acquisition, expected purchase price Asset Acquisition, Price of Acquisition, Expected 2026 (remainder) Long-Term Debt, Maturity, Remainder of Fiscal Year Total long-term liabilities Liabilities, Noncurrent Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Capital expenditures included in accrued expenses Capital Expenditures Incurred but Not yet Paid Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Laboratory and Office Facility Laboratory And Office Facility [Member] Laboratory and office facility. Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Operating expenses: Operating Expenses [Abstract] Prepaid expenses Prepaid Expense, Current Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Other liabilities Other Liabilities, Current Manufacturing Facility Manufacturing Facility [Member] Research Facility in Madison Research Facility In Madison [Member] Research facility in Madison. Balance at beginning of period Balance at end of period Contract With Customer, Liability, Net Contract With Customer, Liability, Net Issuance of common stock under at-the-market offering, net of issuance costs Stock Issued During Period, Value, New Issues Statement [Line Items] Statement [Line Items] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Counterparty Name [Axis] Counterparty Name [Axis] Schedule of Share Activity Related to RSUs Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Subsequent Event [Line Items] Subsequent Event [Line Items] Common Stock Common Stock [Member] Available-for-sale securities Debt Securities, Available-for-Sale Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Non-NEOs Non-NEOs [Member] Corporate debt securities Corporate Debt Securities [Member] Novartis Collaboration Agreement Novartis Collaboration Agreement [Member] Novartis Collaboration Agreement Effect of dilutive securities (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment